What is the 13F Pro Quality Score for ORMP?

13F Pro ranks ORAMED PHARMACEUTICALS INC. (ORMP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ORMP's current score at https://13fpro.ai/research/ORMP (free sign-up required for the full ranking).

Where does 13F Pro source ORMP data?

All ORAMED PHARMACEUTICALS INC. fundamentals and ownership data come directly from SEC EDGAR. ORAMED PHARMACEUTICALS INC. files with the SEC under CIK 1176309. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ORMP in?

ORAMED PHARMACEUTICALS INC. (ORMP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ORMP research updated on 13F Pro?

ORMP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ORAMED PHARMACEUTICALS INC.(ORMP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1176309 ORMP stock profile & AI dashboard →

13F Pro Quality Score

56.3/100

Rank #1,105 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

85.9/100

Profitability

99.6/100

Balance Sheet

99.3/100

Earnings Quality

30.0/100

Free Cash Flow

4.4/100

Institutional Flow

35.0/100

Revenue Scale

1.7/100

Dilution Risk

1.5/100

ORMP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ORAMED PHARMACEUTICALS INC. (ORMP), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORMP at 56.3/100 on a 32-signal composite quality model, placing it at rank #1,105 of 2,879 stocks — the top half of the AI-ranked universe. ORMP scores in the top quartile across profitability (99.6), balance sheet strength (99.3), revenue growth (85.9). Areas of concern include revenue scale (1.7) and free cash flow (4.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), ORAMED PHARMACEUTICALS INC. reports net income of $38.3M, free cash flow of $-2.9M. Top institutional holders of ORMP by reported 13-F value include BML Capital Management,, Aquamarine Financial (Cayman) Ltd, MERCER GLOBAL ADVISORS /ADV, based on the most recent SEC filings. ORMP trades on the Nasdaq exchange and files with the SEC under CIK 1176309. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAMED PHARMACEUTICALS INC. directly from SEC EDGAR. ORAMED PHARMACEUTICALS INC.'s 13F Pro composite quality score has ranged between 8 and 56 since 2021, currently 56.3 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.

✦

Fun facts about ORAMED PHARMACEUTICALS INC.

Quirks, history, and lore behind ORMP — the kind of stuff that makes a stock memorable.

1
The Basics
An Israeli biopharmaceutical company · clinical-stage · listed on Nasdaq · focused on oral drug delivery for diseases managed by injection.
2
The Numbers
A small-cap with minimal product revenue — it runs largely on licensing deals and grants, spending most of its cash on R&D while the pipeline matures.
3
The History
Founded in the early 2000s in Israel, it set out to solve one of medicine's oldest frustrations: why can't patients just swallow a pill instead of taking a shot?
4
The Secret
Its proprietary platform uses protease inhibitors and absorption enhancers to sneak large protein molecules — the kind that normally get destroyed by digestion — safely through the gut wall.
5
The Lore
Its lead candidate is an oral insulin capsule that has advanced into late-stage clinical trials, representing a potential holy grail for the hundreds of millions of diabetics worldwide who dread needles.
6
The Giveaway
Ticker ORMP, headquartered in Jerusalem — this company's entire mission is turning the daily insulin injection into a swallowable pill, one clinical trial at a time.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q3 2026

$38.3M

Free Cash Flow

Q3 2026

$-2.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2023

FY15 —FY19 $2.7MFY20 $2.7MFY23 —

Net Income

—FY 2023

FY15 $-7.2MFY19 $-14.4MFY20 $-11.5MFY23 —

Operating Income

—FY 2023

FY15 $-7.4MFY19 $-14.6MFY20 $-11.8MFY23 —

Total Assets

+250.2% YoY

$156.3MFY 2023

FY15 $26.4MFY19 $34.7MFY20 $44.6MFY23 $156.3M

Total Debt

$99.5MFY 2023

FY15 —FY19 $12.4MFY20 —FY23 $99.5M

Op. Cash Flow

—FY 2023

FY15 $-4.9MFY19 $-12.9MFY20 $-12.4MFY23 —

Metric	FY 2023	FY 2020	FY 2019	FY 2015	FY 2014	FY 2012
Revenue	—	$2.7M +0.3%	$2.7M	—	—	—
Net Income	—	$-11.5M +19.8%	$-14.4M -98.5%	$-7.2M -27.0%	$-5.7M +68.2%	$-17.9M
Operating Income	—	$-11.8M +19.6%	$-14.6M -98.2%	$-7.4M -25.0%	$-5.9M +67.4%	$-18.1M
Total Assets	$156.3M +250.2%	$44.6M +28.8%	$34.7M +31.5%	$26.4M +20.9%	$21.8M +311.8%	$5.3M
Total Debt	$99.5M	—	$12.4M	—	—	—
Operating Cash Flow	—	$-12.4M +3.9%	$-12.9M -161.6%	$-4.9M -21.6%	$-4.1M +62.6%	$-10.9M

AI Insight: ORMP Ratio Trends

ORMP swung to massive operating losses in Q1 2026 despite strong asset returns, signaling severe near-term profitability stress.

• Operating margin collapsed to -182.9% in Q1 2026, worst on record. Q3 2025 ROE peaked at 95.2%, then deteriorated.

• ROIC remained negative throughout 2024–2025 (range: -12.8% to -4.8%), indicating persistent value destruction on invested capital.

• Asset returns strong (ROA 57.0% in Q1 2026, 87.8% in Q3 2025) contrast sharply with negative ROIC, suggesting asset quality or leverage issues.

⚠ Q1 2026 operating margin at -182.9% requires immediate clarification—likely one-time charge or severe operational breakdown.

⚠ Debt-to-equity rose to 0.50 in Q4 2025 (from 0.35 in Q4 2024), potentially limiting financial flexibility amid losses.

Get alerted when ORMP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ORAMED PHARMACEUTICALS INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ORMP

BML Capital Management, LLC
$10.8M3,167,231 sh
Aquamarine Financial (Cayman) Ltd
$7.2M2,112,312 sh
MERCER GLOBAL ADVISORS INC /ADV
$6.5M1,910,540 sh
Gem Investment Advisors, LLC
$5.6M1,640,069 sh
Murchinson Ltd.
$4.5M1,315,294 sh
BOOTHBAY FUND MANAGEMENT, LLC
$2.0M600,716 sh
MARSHALL WACE, LLP
$882.7K259,611 sh
Rathbones Group PLC
$792.3K233,018 sh
DIMENSIONAL FUND ADVISORS LP
$537.7K158,209 sh
WELLS FARGO & COMPANY/MN
$535.8K157,586 sh

Fund	Value	Shares
BML Capital Management, LLC	$10.8M	3,167,231
Aquamarine Financial (Cayman) Ltd	$7.2M	2,112,312
MERCER GLOBAL ADVISORS INC /ADV	$6.5M	1,910,540
Gem Investment Advisors, LLC	$5.6M	1,640,069
Murchinson Ltd.	$4.5M	1,315,294
BOOTHBAY FUND MANAGEMENT, LLC	$2.0M	600,716
MARSHALL WACE, LLP	$882.7K	259,611
Rathbones Group PLC	$792.3K	233,018
DIMENSIONAL FUND ADVISORS LP	$537.7K	158,209
WELLS FARGO & COMPANY/MN	$535.8K	157,586

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ORMP on your watchlist

Track score changes the day ORAMED PHARMACEUTICALS INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ORMP a good stock to buy?

13F Pro's AI-powered analysis of ORAMED PHARMACEUTICALS INC. (ORMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ORMP are available on the ORMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ORMP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ORMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORAMED PHARMACEUTICALS INC.'s investment landscape.